Purdue Pharma and the Opiod Addiction Crisis

內容大綱
By the time Purdue Pharma filed for bankruptcy in 2019, OxyContin had accumulated $35 billion in sales. In a few short years before the bankruptcy filing, the Sackler family siphoned off $13 billion in profits, making them one of the world's wealthiest billionaires. The case discusses the ethically questionable tactics that the Sackler family employed to turbocharge the supply-induced demand for OxyContin, including creating a national pain movement, obtaining FDA approval, downplaying the risks of addiction, ignoring symptoms of addiction, ambitious sales representatives, targeting high prescribers, pampering physicians, addressing regulatory changes, and hiring McKinsey. Purdue Pharma coopted regulators, medical accreditation boards, hospitals, and doctors to do their bidding. As a result, over one million Americans have died from drug overdoses since 2000.
涵蓋主題
新增
新增